Häufigkeit und Topographie von Fernmetastasen bei Patienten mit HNO-Tumoren und ihre onsequenzen für das prätherapeutische Staging

Dietl, B.; Marienhagen, Jörg; Schaefer, Christof; Pohl, Fabian; Kölbl, Oliver

doi:10.1007/s00066-007-1611-7

Cited by 14 publications

(3 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Because patients with locally advanced SCCHN recur locally more often than in distant sites [20, 21], it seems reasonable for patients with EGFR overexpressing tumors to receive more effective locoregional treatments. One such treatment strategy is the concomitant administration of RT with cetuximab.…”

Section: Introductionmentioning

confidence: 99%

MMP9 but Not EGFR, MET, ERCC1, P16, and P-53 Is Associated with Response to Concomitant Radiotherapy, Cetuximab, and Weekly Cisplatin in Patients with Locally Advanced Head and Neck Cancer

Fountzilas

Kalogera‐Fountzila

Lambaki

et al. 2009

Journal of Oncology

View full text Add to dashboard Cite

Concomitant administration of radiotherapy with cisplatin or radiotherapy with cetuximab appear to be the treatment of choice for patients with locally advanced head and neck cancer. In the present retrospective analysis, we investigated the predictive role of several biomarkers in an unselected cohort of patients treated with concomitant radiotherapy, weekly cisplatin, and cetuximab (CCRT). We identified 37 patients treated with this approach, of which 13 (35%) achieved a complete response and 10 (27%) achieved a partial response. Severe side effects were mainly leucopenia, dysphagia, rash, and anemia. Tumor EGFR, MET, ERCC1, and p-53 protein and/or gene expression were not associated with treatment response. In contrast, high MMP9 mRNA expression was found to be significantly associated with objective response. In conclusion, CCRT is feasible and active. MMP9 was the only biomarker tested that appears to be of predictive value in cetuximab treated patients. However, this is a hypothesis generating study and the results should not be viewed as definitive evidence until they are validated in a larger cohort.

show abstract

Section: Introductionmentioning

confidence: 99%

MMP9 but Not EGFR, MET, ERCC1, P16, and P-53 Is Associated with Response to Concomitant Radiotherapy, Cetuximab, and Weekly Cisplatin in Patients with Locally Advanced Head and Neck Cancer

Fountzilas

Kalogera‐Fountzila

Lambaki

et al. 2009

Journal of Oncology

View full text Add to dashboard Cite

show abstract

“…1 Distant metastases are present in 4% of the patients at the time of presentation, with many more subsequently developing distant disease. 2 The most common metastatic sites in advanced BC are bone, lungs, pleura, liver, and brain. Head and neck (H&N) is a rare site for metastases.…”

mentioning

confidence: 99%

Breast Cancer Metastasis to Nasal Septum

KAPAN,

ÖZGÜR,

ÜNÇEL

et al. 2023

J Oncol Sci

View full text Add to dashboard Cite

The most common malignancy and leading cause of cancer-related deaths in women is breast cancer (BC). Despite significant progress in the management of BC, advanced disease remains an important cause of mortality. 1 Distant metastases are present in 4% of the patients at the time of presentation, with many more subsequently developing distant disease. 2 The most common metastatic sites in advanced BC are bone, lungs, pleura, liver, and brain. Head and neck (H&N) is a rare site for metastases. In most cases, bony involvement of jaws and supraclavicular lymphadenopathy is observed. 3 The metastatic spread to the nasal cavity has been rarely reported, with most cases of renal cell carcinoma. 4-6 BC metastases to the nasal cavity are extremely rare. [7][8][9] Herein, we present a case of nasal septum metastasis from BC. CASE REPORTA 54-year-old female patient presented with a lump in the right breast. She was diagnosed with BC, and a right radical mastectomy and axillary lymph node dissection was performed. The pathology revealed a triple negative invasive ductal carcinoma, T3N0M0. She subsequently received four cycles of adjuvant doxorubicin-cyclophosphamide and 12 cycles of weekly paclitaxel. However, she presented with bilateral pulmonary and bony lesions after 2 years of follow-up. Additionally, she had locoregional recurrence with an ulcerated mass on the surgical site. She had palliative 66 Gy radiotherapy to the anterior wall of the right thorax. She was further treated with palliative 6 cycles of docetaxel, 9 cycles of docetaxel-181 181 181

show abstract

“…Die Literaturangaben über das Auftreten von Fernmetastasen beim zervikalen CUP-Syndrom variieren zwischen 11 und 30%(Strojan und Anicin 1998;Ligey et al 2009;Perkins et al 2012).Möglicherweise liegt die Ursache dieser großen Spannbreite im unterschiedlichen Umfang der diagnostischen Maßnahmen, die im Rahmen der Nachsorgeuntersuchung durchgeführt wurden. Diese variierten offenbar zwischen den verschiedenen Studien in nicht unerheblichem Umfang(Dietl et al 2007). Ebenfalls zu berücksichtigen sind die unterschiedlichen Zusammensetzungen der jeweiligen Patientenkollektive und das jeweilige Studiendesign León et al (2000).…”

unclassified

Zervikale Lymphknotenmetastasen bei unbekanntem Primärtumor - Eine retrospektive Analyse zu Diagnostik und Therapie

Blomeyer¹

View full text Add to dashboard Cite

Häufigkeit und Topographie von Fernmetastasen bei Patienten mit HNO-Tumoren und ihre onsequenzen für das prätherapeutische Staging

Cited by 14 publications

References 35 publications

MMP9 but Not EGFR, MET, ERCC1, P16, and P-53 Is Associated with Response to Concomitant Radiotherapy, Cetuximab, and Weekly Cisplatin in Patients with Locally Advanced Head and Neck Cancer

MMP9 but Not EGFR, MET, ERCC1, P16, and P-53 Is Associated with Response to Concomitant Radiotherapy, Cetuximab, and Weekly Cisplatin in Patients with Locally Advanced Head and Neck Cancer

Breast Cancer Metastasis to Nasal Septum

Zervikale Lymphknotenmetastasen bei unbekanntem Primärtumor - Eine retrospektive Analyse zu Diagnostik und Therapie

Contact Info

Product

Resources

About